Skip to main content

Muthoot Finance to raise Rs 2,000 crore through secured NCDs; shares trade in the red

The company has announced its 23rd series of public issue of secured redeemable non-convertible debentures (NCDs) of the face value of Rs 1,000 each.

Shares of Muthoot Finance declined almost 3 percent in intraday trade even as the company revealed its plans of secured non-convertible debentures (NCDs).

The company, on October 26, announced its 23rd series of public issue of secured redeemable NCDs of the face value of Rs 1,000 each.

In a press release, the company said the issue is with a base issue size of Rs 100 crore with an option to retain oversubscription up to Rs 1,900 crore, aggregating up to a tranche limit of Rs 2,000 crore.



"The issue will open on October 27, 2020, and will close on November 20, 2020, with an option to close on such earlier date or an extended date as may be decided by the board of directors or NCD committee," said the media release.

"The secured NCDs proposed to be issued under this issue have been rated CRISIL AA/Positive by CRISIL and [ICRA] AA (Stable) by ICRA. The rating of the secured NCDs by CRISIL and ICRA indicates a high degree of safety regarding timely servicing of financial obligations," Muthoot Finance said.

Moreover, the NCDs are proposed to be listed on BSE. The allotment will be on a first come first serve basis.

"There are six investment options for secured NCDs with ‘monthly’ or ‘annual’ interest payment frequency or ‘on maturity redemption’ payments with coupon ranging from 7.15 percent per annum to 8 percent per annum," Muthoot Finance said.

George Alexander Muthoot, Managing Director, Muthoot Finance Ltd, said, "In the present scenario of lower interest rates and expectations of interest rates falling further, our issue offers safe long-term investment options with high stable returns to investors."

"The issue will augment the company’s long-term funding requirements thereby supporting the stable growth that our company envisages. We expect the current issue, too, be well received by the market in line with our previous NCD issues as there are limited comparable investment avenues available," he added.

Shares of the company pared losses and traded 0.11 percent down at Rs 1,183 on BSE at 1400 hours.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more